Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How has the glucagon-like peptide (glp)-1 agonists weight loss drugs market size changed in recent years, and what is the outlook ahead?
The glucagon-like peptide (GLP) -1 agonists weight loss drugs market size has grown rapidly in recent years. It will grow from $13.38 billion in 2024 to $15.63 billion in 2025 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to the rising prevalence of obesity, increasing cases of type 2 diabetes, growing awareness of obesity-related health risks, rising healthcare expenditure, increasing focus on chronic disease management, and improved access to healthcare.
The glucagon-like peptide (GLP) -1 agonists weight loss drugs market size is expected to see rapid growth in the next few years. It will grow to $28.91 billion in 2029 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to increasing demand for effective weight loss solutions, expansion of drug indications beyond diabetes, rising investments in research and development, growing adoption of personalized medicine, and increasing awareness through direct-to-consumer marketing. Major trends in the forecast period include the development of oral glucagon-like peptide (GLP)-1 formulations, advancements in sustained-release drug delivery, integration of digital health tools for monitoring, use of artificial intelligence in drug discovery and development, and innovation in peptide engineering for enhanced efficacy.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp
What are the top economic and technological drivers pushing glucagon-like peptide (glp)-1 agonists weight loss drugs market growth?
The rising prevalence of obesity is expected to propel the growth of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market going forward. Obesity refers to a medical condition characterized by excessive body fat accumulation that presents a risk to health. Obesity rates are growing due to unhealthy eating habits where people consume more fast food and sugary drinks, lacking proper nutrition and balance. As the number of individuals affected by obesity and its related complications continues to rise, the demand for effective treatment options is increasing, thereby driving the use of glucagon-like peptide (GLP-1) agonist weight loss drugs for their proven ability to support weight loss and enhance metabolic health. For instance, in March 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, in 2022, one in eight people globally were living with obesity. Among the 2.5 billion overweight adults, approximately 890 million were classified as having obesity. Additionally, overall, 43% of the global adult population was overweight, with 16% falling into the obese category. Therefore, the rising prevalence of obesity is driving the growth of glucagon-like peptide (GLP)-1 agonist weight loss drugs market.
How is the glucagon-like peptide (glp)-1 agonists weight loss drugs market segmented by product, application, and end-user?
The glucagon-like peptide (GLP)-1 agonists weight loss drugs market covered in this report is segmented –
1) By Drugs: Semaglutide, Liraglutide, Tirzepatide, Other Drugs
2) By Route of Administration: Parenteral, Oral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Pharmacies
Subsegments:
1) By Semaglutide: Ozempic, Wegovy, Rybelsus
2) By Liraglutide: Saxenda, Victoza
3) By Tirzepatide: Mounjaro, Zepbound
4) By Other Drugs: Exenatide, Dulaglutide, Albiglutide, Efpeglenatide
View The Full Market Report:
What evolving trends are creating new opportunities in the glucagon-like peptide (glp)-1 agonists weight loss drugs market?
Major companies operating in the glucagon-like peptide (GLP)-1 agonist weight loss drugs market are developing innovative obesity treatment solutions to enhance efficacy and improve patient outcomes. Obesity treatment solutions refer to therapies that mimic the GLP-1 hormone to regulate appetite, enhance satiety, and promote weight loss. These drugs help manage obesity by improving metabolic function and supporting long-term weight control. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, received US Food and Drug Administration approval for Zepbound, a medication for chronic weight management in adults with obesity or overweight who have related health conditions such as type 2 diabetes or sleep apnea. The drug works by activating GIP and GLP-1 hormone receptors to suppress appetite and enhance metabolic function.
Which leading companies are dominating the glucagon-like peptide (glp)-1 agonists weight loss drugs market landscape?
Major companies operating in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc, Amgen Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, Jiangsu Hengrui Medicine Co. Ltd, BioAge Labs, Hanmi Pharmaceutical, Innovent Biologics Inc., Viking Therapeutics Inc., Structure Therapeutics Inc., Zealand Pharma A/S, Regor Therapeutics Inc., I-Mab Biopharma (Shanghai) Co. Ltd., Altimmune Inc., TheracosBio LLC., Oramed Pharmaceuticals.
Which geographic areas are expected to offer the highest growth opportunities in theglucagon-like peptide (glp)-1 agonists weight loss drugs market?
North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024. The regions covered in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24226&type=smp
Need Customized Data On Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24226&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
